Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.

Liu W, Ren HY, Dong YJ, Wang LH, Yin Y, Li Y, Qiu ZX, Cen XN, Shi YJ.

Int J Hematol. 2012 Dec;96(6):764-72. doi: 10.1007/s12185-012-1195-6.

PMID:
23179902
2.

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.

Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villarón E, Schenkein D, Pandiella A, San Miguel J.

Blood. 2006 May 1;107(9):3575-83.

3.

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

He S, Cao Q, Qiu Y, Mi J, Zhang JZ, Jin M, Ge H, Emerson SG, Zhang Y, Zhang Y.

J Immunol. 2008 Dec 1;181(11):7581-92.

4.

Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.

Maseda D, Meister S, Neubert K, Herrmann M, Voll RE.

Cell Death Differ. 2008 Mar;15(3):600-12. doi: 10.1038/sj.cdd.4402297.

5.

Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.

Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, Daniel V, Naujokat C.

Immunology. 2008 Jun;124(2):234-46. doi: 10.1111/j.1365-2567.2007.02761.x.

8.

Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD.

Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, Craddock C, Malladi R, Moss PA.

Blood. 2012 Nov 15;120(20):4246-55. doi: 10.1182/blood-2012-02-413260.

9.
10.

Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.

Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Caballero-Velazquez T, Gutierrez-Cossío S, Hernández-Campo P, Díez-Campelo M, Herrero-Sanchez C, Rodriguez-Serrano C, Santamaría C, Sánchez-Guijo FM, Del Cañizo C, San Miguel JF.

Haematologica. 2009 Jul;94(7):975-83. doi: 10.3324/haematol.2008.005017.

11.

JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.

Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R, Tesoriere G.

Apoptosis. 2006 Apr;11(4):607-25.

PMID:
16528474
12.

The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.

Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.

Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4706-19.

PMID:
17898295
14.

The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.

Yerlikaya A, Okur E, Ulukaya E.

Tumour Biol. 2012 Oct;33(5):1385-92. doi: 10.1007/s13277-012-0386-3.

PMID:
22477712
15.

CXCR3 is induced early on the pathway of CD4+ T cell differentiation and bridges central and peripheral functions.

Rabin RL, Alston MA, Sircus JC, Knollmann-Ritschel B, Moratz C, Ngo D, Farber JM.

J Immunol. 2003 Sep 15;171(6):2812-24.

16.

[Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].

Fu YB, Sun QX, Meng FY, Xie J, Zhou GB.

Zhonghua Yi Xue Za Zhi. 2006 Sep 12;86(34):2413-6. Chinese.

PMID:
17156654
17.

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.

Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA.

Mol Cancer Ther. 2006 Sep;5(9):2378-87.

19.

Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production.

Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, Fishbein MC, Belperio J, Strieter RM, Bonavida B, Ardehali A.

J Immunol. 2004 Jun 15;172(12):7417-24.

20.

CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation.

Giegold O, Ogrissek N, Richter C, Schröder M, Herrero San Juan M, Pfeilschifter JM, Radeke HH.

J Immunol. 2013 Apr 1;190(7):3696-705. doi: 10.4049/jimmunol.1101293.

Items per page

Supplemental Content

Support Center